Literature DB >> 23928474

Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction.

Sérgio Barra1, Inês Almeida, Francisca Caetano, Rui Providência, Luís Paiva, Paulo Dinis, António Leitão Marques.   

Abstract

INTRODUCTION: A new risk stratification scheme incorporating the original CHADS2 score and renal function, entitled R(2)CHADS(2), was validated in the ROCKET-AF and ATRIA study cohorts. AIMS: Adjusting and validating a modified R-CHA2DS2VASc score as a predictor of ischaemic stroke and all-cause mortality in patients discharged following admission for a Myocardial Infarction (MI).
MATERIALS AND METHODS: Observational retrospective single-centre cohort study including 1711 patients admitted with MI and discharged alive. We tested the prognostic performance of R-CHA2DS2VASc, based on the original CHA2DS2VASc score with few modifications (addition of renal function parameters [glomerular filtration rate and urea], performance of a revascularization procedure and history of atrial fibrillation). R-CHA2DS2VASc was evaluated for its discriminative performance and calibration in the prediction of ischaemic stroke (primary endpoint), all-cause mortality and a composite endpoint of ischemic stroke plus all-cause mortality (secondary outcomes) during follow-up.
RESULTS: R-CHA2DS2VASc score's areas under the curve (AUC) for the occurrence of primary and secondary outcomes were: Ischaemic stroke: AUC 0.717 ± 0.031, p<0.001 (vs. 0.681 ± 0.043 for CHA2DS2VASc, p=0.290); all-cause mortality during follow-up: AUC 0.811 ± 0.014, p<0.001 (vs. 0.782 ± 0.019 for GRACE, p=0.245); composite endpoint: AUC 0.803 ± 0.014, p<0.001. The integrated discrimination improvement index (IDI) and relative IDI for the primary endpoint were 0.015 and 28.2%, respectively, while the IDI and relative IDI for all-cause mortality were 0.13 and 72.1%, suggesting a large improvement in risk stratification. An R-CHA2DS2VASc score below 3 had a negative predictive value of 98.6% for the occurrence of ischaemic stroke.
CONCLUSIONS: The modified R-CHA2DS2VASc score has shown good calibration and high discriminative performance in the prediction of post-discharge ischaemic stroke and all-cause mortality. The inclusion of renal function in thromboembolic risk predicting schemes seems warranted.
© 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACCU; AF; AUC; Acute Cardiac Care Unit; Area Under the Curve; Atrial Fibrillation; BUN; Blood Urea Nitrogen; CAD; CHA2DS2-VASc score; CT; Computed Tomography; Coronary Artery Disease; GFR; GRACE score; Glomerular Filtration Rate; IDI; Integrated Discrimination Improvement (Index); Ischemic stroke; MDRD; MI; Modified Diet in Renal Disease; Mortality; Myocardial Infarction; Myocardial infarction; ROC; Receiver Operating Characteristic; Renal disease

Mesh:

Year:  2013        PMID: 23928474     DOI: 10.1016/j.thromres.2013.06.025

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Management of Atrial Fibrillation in Patients With Kidney Disease.

Authors:  Yee C Lau; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

2.  Elevated Blood Urea Nitrogen is Associated With Critical Limb Ischemia in Peripheral Arterial Disease Patients.

Authors:  Thomas Gary; Martin Pichler; Gernot Schilcher; Franz Hafner; Gerald Hackl; Peter Rief; Philipp Eller; Marianne Brodmann
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

3.  Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?

Authors:  Belén Álvarez-Álvarez; Sergio Raposeiras-Roubín; Emad Abu-Assi; Cristina Cambeiro-González; Santiago Gestal-Romaní; Andrea López-López; Noelia Bouzas-Cruz; María Castiñeira-Busto; Ozoda Saidhodjayeva; Alfredo Redondo-Diéguez; Eva Pereira López; José María García-Acuña; José Ramón González-Juanatey
Journal:  Open Heart       Date:  2014-12-22

Review 4.  Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.

Authors:  Laura Ueberham; Nikolaos Dagres; Tatjana S Potpara; Andreas Bollmann; Gerhard Hindricks
Journal:  Adv Ther       Date:  2017-09-27       Impact factor: 3.845

Review 5.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

6.  CHA2DS2-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation.

Authors:  Bartosz Hudzik; Janusz Szkodziński; Michal Hawranek; Andrzej Lekston; Lech Poloński; Mariusz Gąsior
Journal:  Acta Diabetol       Date:  2016-06-23       Impact factor: 4.280

7.  CHA2DS2-VASc score as predictor of ischemic stroke in patients undergoing coronary artery bypass grafting and percutaneous coronary intervention.

Authors:  Yaohua Tian; Chenlu Yang; Hui Liu
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

8.  CHA2DS2-VASc and R2-CHA2DS2-VASc scores predict in-hospital and post-discharge outcome in patients with myocardial infarction.

Authors:  Michał Węgiel; Tomasz Rakowski; Artur Dziewierz; Joanna Wojtasik-Bakalarz; Danuta Sorysz; Stanisław Bartuś; Andrzej Surdacki; Dariusz Dudek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-12-11       Impact factor: 1.426

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.